ClinicalTrials.gg
CompletedNCT06850051Updated Jan 16, 2026

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

A Phase 1 interventional study of TIV-HA Vaccine formulation 1 at low dose and TIV-HA formulation 1 at high dose in Healthy Volunteers, Influenza Vaccination and Respiratory Syncytial Virus Vaccination, sponsored by Sanofi. Completed at 6 sites in Australia. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Sanofi · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
71st of 126
270 · median 305
Started
2025
with 2 others
Phase 1
11 of 139
none open now
Registered
134th of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 71st largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 in phase 1, and was the 134th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine in healthy participants 18 to 49 years of age. A lipid nanoparticle will be used in this study.

Overall, the study is designed to:

  • Assess the safety profile of the candidate formulations
  • Describe the immunogenicity profile of the candidate formulations
  • Eligible participants will be randomized to receive a single intramuscular injection of either one of the vaccine formulations.

Participants will be provided with a diary to solicit reporting of injection site reactions and systemic reactions, unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest AESIs).

Participants will also be required to record their daily temperature on the diary.

Read the detailed description

The duration of study participation will be approximately 6 months for each participant.

03

Conditions studied

  • Healthy Volunteers
  • Influenza Vaccination
  • Respiratory Syncytial Virus Vaccination
  • Parainfluenza Vaccination
  • Human Metapneumovirus Vaccination

Keywords

  • influenza
  • respiratory syncytial virus
  • parainfluenza
  • human metapneumovirus
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 49 years on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile OR
    • Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.

Exclusion criteria

Exclusion Criteria:

- Any medical condition or circumstance which, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    Group 1 trivalent influenza vaccine-hemagglutinin (TIV-HA) formulation 1 at high dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the TIV-HA vaccines according to their randomization schedule.

    Biological: TIV-HA formulation 1 at high dose

  • Experimental
    Group 2 TIV-HA formulation 2 at high dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the TIV-HA vaccines according to their randomization schedule.

    Biological: TIV-HA formulation 2 at high dose

  • Experimental
    Group 3 TIV-HA formulation 1 at low dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the TIV-HA vaccines according to their randomization schedule.

    Biological: TIV-HA Vaccine formulation 1 at low dose

  • Experimental
    Group 4 TIV-HA formulation 2 at low dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the TIV-HA vaccines according to their randomization schedule.

    Biological: TIV-HA formulation 2 at low dose

  • Experimental
    Group 5 RSV/hMPV/PIV3 formulation 1 at high dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV/PIV3 vaccines according to their randomization schedule.

    Biological: RSV/hMPV/PIV3 formulation 1 at high dose

  • Experimental
    Group 6 RSV/hMPV/PIV3 formulation 2 at high dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV/PIV3 vaccines according to their randomization schedule.

    Biological: RSV/hMPV/PIV3 formulation 2 at high dose

  • Experimental
    Group 7 RSV/hMPV/PIV3 formulation 1 at low dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV/PIV3 vaccines according to their randomization schedule.

    Biological: RSV/hMPV/PIV3 formulation 1 at low dose

  • Experimental
    Group 8 RSV/hMPV/PIV3 formulation 2 at low dose

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV/PIV3 vaccines according to their randomization schedule.

    Biological: RSV/hMPV/PIV3 formulation 2 at low dose

  • Active comparator
    Group 9 recombinant influenza vaccine quadrivalent (RIV4)

    Participants will receive a single IM (Intramuscular) injection on day 1 of the RIV4 vaccine according to their randomization schedule.

    Biological: RIV4 (Supemtek®)

Interventions

  • BiologicalTIV-HA Vaccine formulation 1 at low dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalTIV-HA formulation 1 at high dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalTIV-HA formulation 2 at low dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalTIV-HA formulation 2 at high dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalRSV/hMPV/PIV3 formulation 2 at low dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalRSV/hMPV/PIV3 formulation 1 at high dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalRSV/hMPV/PIV3 formulation 2 at high dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalRSV/hMPV/PIV3 formulation 1 at low dose

    Suspension for injection in a vial. Route of administration: IM injection

  • BiologicalRIV4 (Supemtek®)

    Solution for injection in a prefilled syringe. Route of administration: IM injection

06

What researchers measure

Primary outcomes

  1. Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccination

    Number of participants with unsolicited systemic AEs

    Time frame: Within 30 minutes after each vaccination

  2. Presence of solicited injection site and systemic reactions (ie, pre-listed in the participant's diary and in the eCRF (electronic case report form) occurring through 7 days after vaccination

    Number of participants with solicited injection site and systemic reactions

    Time frame: Through 7 days after each vaccination

  3. Presence of unsolicited AEs reported through 28 days after vaccination

    Number of participants with unsolicited AEs

    Time frame: Through 28 days after each vaccination

  4. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest) throughout the study

    : Number of participants with SAEs and AESIs

    Time frame: Throughout study, approximately 6 months

  5. Presence of out-of-range biological test results (including shift from baseline values) through 7 days after vaccination

    : Number of participants with out-of-range biological tests

    Time frame: Through 7 days after vaccination

  6. Hemagglutinin Inhibition Assay (HAI) antibody (Ab) response to each homologous influenza strain at Day 1 and Day 29

    Time frame: Day 1 and Day 29

  7. RSV A, hMPV A and PIV3 serum neutralizing antibodies (nAb) titers at Day 1 and Day 29

    Time frame: Day 1 and Day 29

Secondary outcomes

  1. RSV B and hMPV A nAb titers at Day 1 and Day 29

    Time frame: Day 1 and Day 29

  2. Neutralization Test (NT) Ab response to each homologous influenza strain at Day 29

    Time frame: Day 29

07

Study locations

6 sites
  • Paratus Clinical
    Blacktown, New South Wales 2148, Australia
  • Paratus Clinical
    Herston, Queensland 4006, Australia
  • University of Sunshine Coast Clinical Trials
    Morayfield, Queensland 4506, Australia
  • University of Sunshine Coast Clinical Trials
    South Brisbane, Queensland 4101, Australia
  • Griffith University
    Southport, Queensland 4215, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Dec 2025, 8 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 27, 2025
StartActual
Mar 19, 2025
Primary completionActual
Dec 11, 2025
CompletionActual
Dec 11, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06850051
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Mar 19, 2025
Primary completion
Dec 11, 2025
Completion
Dec 11, 2025
Last update
Jan 16, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion